Amgen

Amgen, a US-headquartered Pharmaceutical Preparation Manufacturing company, reported its total carbon emissions for 2024 as approximately 1.86 billion kg CO2e. This includes Scope 1 emissions of approximately 147.35 million kg CO2e, Scope 2 emissions of about 14 million kg CO2e, and Scope 3 emissions of approximately 1.71 billion kg CO2e.

Looking at previous years, Amgen's Scope 1 and 2 emissions were approximately 165 million kg CO2e in 2023, 165 million kg CO2e in 2022, 191 million kg CO2e in 2021, 275 million kg CO2e in 2020, and 296 million kg CO2e in 2019.

Amgen has set several climate commitments. The company is committed to achieving carbon neutrality for its owned and operated facilities and operations (Scopes 1 and 2) by 2027. It also aims for 100% renewable electricity use at all feasible operations by 2027, which is expected to result in a 50% reduction in operational carbon emissions.

Furthermore, Amgen has Science Based Targets initiative (SBTi) validated targets. The company commits to reducing absolute Scope 1 and 2 GHG emissions by 55% by 2027, from a 2019 base year. This target is consistent with reductions required to keep warming to 1.5°C. Amgen also pledges to increase annual sourcing of renewable electricity from 29% in 2019 to 100% by 2027, and to continue this 100% renewable electricity sourcing through 2030. Additionally, the company commits that 73% of its suppliers by spend, covering upstream purchased goods and services and capital goods, will have science-based targets by 2027.

As of 2023, Amgen had achieved 54% of its targeted reductions for Scope 1 and 2 carbon emissions from a 2019 baseline.